How Will Rhythm Biosciences Scale ColoSTAT® with New Manufacturing Deal?
Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.
- Multi-year supply agreement with Quansys Biosciences
- ISO13485-certified manufacturing facilities secured
- Supports ColoSTAT® Access Program and commercial launch
- Reduces operational and scale-up risks
- Fixed pricing framework for initial two years
Strategic Manufacturing Partnership Secured
Rhythm Biosciences Ltd (ASX, RHY), an Australian medical diagnostics innovator, has formalised a key commercial manufacturing agreement with Quansys Biosciences, a US-based specialist in multiplex immunoassay production. This multi-year deal establishes Quansys as the contract manufacturer for ColoSTAT® reagent kits, a critical component in Rhythm’s blood-based colorectal cancer detection test.
The agreement provides Rhythm with scalable manufacturing capacity through Quansys’ ISO13485-certified facilities, ensuring quality-assured production aligned with regulatory standards. This partnership follows two years of collaborative assay development and validation, marking a significant operational milestone as Rhythm prepares for broader commercial deployment.
Supporting Commercial Rollout and Access Program
ColoSTAT® is designed to detect colorectal cancer early through a simple blood test measuring five protein biomarkers. The new manufacturing arrangement supports the ColoSTAT® Access Program, enabling Rhythm to meet anticipated testing volumes with reliable supply. The agreement includes provisions for minimum order volumes and a fixed pricing framework for the first two years, providing cost predictability as Rhythm scales production.
Rhythm’s CEO and Managing Director, Dr David Atkins, highlighted the importance of this partnership, noting that Quansys’ proven expertise and quality systems are vital to supporting the upcoming commercial launch and ensuring operational resilience.
Reducing Risk and Building Infrastructure
By partnering with an experienced manufacturer like Quansys, Rhythm mitigates risks associated with manufacturing scale-up and quality control. Quansys Biosciences CEO Adam Brown expressed enthusiasm for supporting a transformative colorectal cancer diagnostic, aligning with their mission to empower clinical advancements through high-quality multiplex immunoassays.
The agreement also leverages Quansys’ established logistics and distribution infrastructure, positioning Rhythm to meet global demand efficiently. This strategic move reflects Rhythm’s commitment to building robust commercial infrastructure ahead of regulatory approvals and market entry.
Looking Ahead
Rhythm continues to advance the ColoSTAT® Access Program alongside regulatory and commercial partnership discussions. While the announcement does not disclose detailed financial terms or volume commitments, it signals confidence in ColoSTAT®’s commercial potential and Rhythm’s readiness to scale.
As colorectal cancer remains a leading cause of cancer mortality worldwide, the successful commercialisation of ColoSTAT® could have meaningful impacts on early detection and healthcare costs. Investors and industry watchers will be keen to monitor upcoming regulatory milestones and market uptake.
Bottom Line?
This manufacturing deal sets the stage for Rhythm Biosciences to transition ColoSTAT® from development to commercial reality, but regulatory and market execution remain critical next steps.
Questions in the middle?
- What are the specific volume commitments and financial terms of the Quansys manufacturing agreement?
- How soon can Rhythm Biosciences expect regulatory approvals to enable full commercial launch?
- What partnerships or distribution channels will Rhythm leverage to maximise ColoSTAT® market penetration?
